Amgen Inc. (NASDAQ:AMGN) Stake Boosted by First Financial Bankshares Inc

First Financial Bankshares Inc boosted its position in Amgen Inc. (NASDAQ:AMGN - Free Report) by 2.0% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 229,053 shares of the medical research company's stock after purchasing an additional 4,476 shares during the period. Amgen comprises 1.3% of First Financial Bankshares Inc's investment portfolio, making the stock its 25th biggest position. First Financial Bankshares Inc's holdings in Amgen were worth $59,700,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the company. Swedbank AB grew its holdings in Amgen by 1.1% during the 3rd quarter. Swedbank AB now owns 538,899 shares of the medical research company's stock valued at $173,639,000 after buying an additional 5,751 shares during the last quarter. Quest Partners LLC grew its holdings in Amgen by 1,568.7% during the 3rd quarter. Quest Partners LLC now owns 1,919 shares of the medical research company's stock valued at $618,000 after buying an additional 1,804 shares during the last quarter. Joseph Group Capital Management grew its holdings in Amgen by 15.7% during the 3rd quarter. Joseph Group Capital Management now owns 8,633 shares of the medical research company's stock valued at $2,782,000 after buying an additional 1,169 shares during the last quarter. Pathstone Holdings LLC grew its holdings in Amgen by 1.7% during the 3rd quarter. Pathstone Holdings LLC now owns 98,605 shares of the medical research company's stock valued at $31,772,000 after buying an additional 1,694 shares during the last quarter. Finally, Caprock Group LLC grew its holdings in Amgen by 6.6% during the 3rd quarter. Caprock Group LLC now owns 16,424 shares of the medical research company's stock valued at $5,292,000 after buying an additional 1,017 shares during the last quarter. 76.50% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Insider Buying and Selling

In related news, EVP David M. Reese sold 25,225 shares of the business's stock in a transaction dated Friday, February 21st. The stock was sold at an average price of $304.44, for a total value of $7,679,499.00. Following the transaction, the executive vice president now owns 36,922 shares in the company, valued at approximately $11,240,533.68. The trade was a 40.59 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Nancy A. Grygiel sold 1,589 shares of the company's stock in a transaction that occurred on Wednesday, February 5th. The shares were sold at an average price of $304.47, for a total value of $483,802.83. Following the sale, the senior vice president now owns 7,210 shares in the company, valued at $2,195,228.70. The trade was a 18.06 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 69,341 shares of company stock worth $20,644,335. 0.69% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

AMGN has been the topic of several analyst reports. Deutsche Bank Aktiengesellschaft decreased their price objective on Amgen from $305.00 to $285.00 in a report on Wednesday, November 27th. Johnson Rice set a $294.00 price objective on Amgen in a research report on Wednesday, March 5th. Wells Fargo & Company reaffirmed an "equal weight" rating on shares of Amgen in a research report on Wednesday, February 5th. Piper Sandler Companies reaffirmed an "overweight" rating and issued a $310.00 price objective on shares of Amgen in a research report on Thursday, January 2nd. Finally, StockNews.com downgraded Amgen from a "strong-buy" rating to a "buy" rating in a research report on Wednesday, December 18th. Two research analysts have rated the stock with a sell rating, ten have given a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus target price of $314.04.

Amgen Stock Up 0.3 %

Shares of AMGN traded up $1.00 during midday trading on Friday, reaching $316.04. 9,994,350 shares of the company were exchanged, compared to its average volume of 2,553,454. The stock has a 50-day moving average price of $297.24 and a 200-day moving average price of $298.80. The company has a market cap of $169.78 billion, a price-to-earnings ratio of 41.86, a P/E/G ratio of 2.63 and a beta of 0.53. Amgen Inc. has a 1-year low of $253.30 and a 1-year high of $346.85. The company has a current ratio of 1.26, a quick ratio of 0.95 and a debt-to-equity ratio of 9.62.

Amgen (NASDAQ:AMGN - Get Free Report) last issued its quarterly earnings data on Tuesday, February 4th. The medical research company reported $5.31 EPS for the quarter, topping analysts' consensus estimates of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%. Research analysts expect that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Friday, May 16th will be paid a $2.38 dividend. This represents a $9.52 annualized dividend and a dividend yield of 3.01%. The ex-dividend date is Friday, May 16th. Amgen's dividend payout ratio (DPR) is 126.09%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.